New York, June 15 - Aeterna Zentaris Inc. said it received commitments to buy $12.1 million of stock and warrants in registered direct offering.
The company will sell 8.8 million shares at $1.3725 each and warrants exercisable for 4.4 million shares at $1.3725. The warrants will expire after five years.
Rodman & Renshaw, LLC is the agent for the deal.
Settlement is expected on June 18.
Proceeds will be used to fund the company's AEZS-108, AEZS-112 and AEZS-130 programs and for other general corporate and working capital purposes.
Aeterna Zentaris is a biopharmaceutical company focused on endocrine therapy and oncology based in Quebec City, Quebec.
| Issuer: | Aeterna Zentaris Inc.
|
| Issue: | Share and warrants
|
| Amount: | $12.1 million
|
| Shares: | 8.8 million
|
| Price: | $1.3725
|
| Warrants: | For 4.4 million shares
|
| Warrant expiration: | 5 years
|
| Warrant strike price: | $1.3725
|
| Agent: | Rodman & Renshaw, LLC
|
| Pricing date: | June 15
|
| Settlement date: | June 18
|
| Stock symbol: | Nasdaq: AEZS
|
| Stock price: | $1.31 at close June 15
|
| Market capitalization: | $97.36 million
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
